Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies
Systematic review reveals high response rates and low severe adverse events for liso-cel in relapsed large B-cell lymphoma, suggesting effective treatment options.
Key Points
This research aims to assess the efficacy and safety of lisocabtagene maraleucel in treating relapsed or refractory large B-cell lymphoma.
Conducted a systematic review and meta-analysis of clinical trials and real-world studies
Evaluated liso-cel monotherapy in relapsed or refractory large B-cell lymphoma
Analyzed 11 studies including 1206 patients with pooled proportions using random-effects models.
Pooled overall response rate (ORR) was 78%
Pooled complete response (CR) rate was 60%
Severe grade ≥ 3 adverse events occurred in 2% (CRS) and 8% (ICANS) respectively.